HYDROXYUREA IN THE TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA IN AN ADVANCED-STAGE

Hydroxyurea in the treatment of chronic myelocytic leukemia in an adva nced stage. O. M. Votyakova, M. A. Volkova, S. V. Lepkov, A. V. Mishen in, N. A. Obidina. Cancer Research Centre, Moscow, Russia. 53 patients with chronic myelocytic leukemia in the chronic phase received treatm ent with hydroxyurea. 40 of them were previously untreated, 13 had pre viously received mileran, dibrommannitol or 6-MP. The initial dose of the drug was 500-4000 mg daily. Maintenance dose during the clinicohem atological remission was 500-2000 mg daily. The remission (2-58 months , median - 12 months) was achieved in 45 patients (85%). Median durati on of the chronic phase of the disease reached 36 months, median survi val 48 months.